News & Updates
Filter by Specialty:
Sabizabulin for metastatic castration-resistant prostate cancer clears phase early trial
10 Jul 2022
The oral cytoskeleton disruptor sabizabulin shows antitumour activity in men with metastatic castration-resistant prostate cancer, while having a favourable safety profile, as shown in the results of a phase Ib/II trial.
Sabizabulin for metastatic castration-resistant prostate cancer clears phase early trial
10 Jul 2022
Triplet regimen works against triple-negative breast cancer
08 Jul 2022
Treatment with a novel combination of famitinib, camrelizumab, and nab-paclitaxel appears safe and effective in patients with advanced immunomodulatory triple-negative breast cancer (TNBC), as shown in the results of the phase II FUTURE-C-Plus trial.
Triplet regimen works against triple-negative breast cancer
08 Jul 2022
CVD prevention better with ACE inhibitor–statin combo than monotherapy
08 Jul 2022
In patients with hypertension, combined treatment with angiotensin-converting enzyme (ACE) inhibitors plus statins reduces the risk of developing cardiovascular disease (CVD) at a greater magnitude as compared with ACE inhibitor monotherapy, a study has found.
